Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

RHONE-POULENC RORER's NASACORT Rx NASAL INHALER APPROVED by FDA for the treatment of allergic rhinitis on July 11, the company announced July 15. The active ingredient of Nasacort -- triamcinolone -- is the same as in Rorer's metered-dose inhaled astha medication Azmacort. Triamicinolone is also marketed by Rugby Labs in a 0.1% ointment and cream as a topical corticosteroid. Nasacort is indicated for "seasonal and perennial allergic rhinitis." The product is approved for rhinitis in adults and children over 12 years old. Nasacort is to be administered once per day, two puffs of spray per nostril. A 10 gm metered-dose Nasacort inhaler provides 100 doses at 55 mg per dose. Nasacort is rated "3C" (new formulation with little or no therapeutic gain over already marketed drugs) by FDA. FDA's review of the once-a-day nasal formulation of triamicinolone acetonide was conducted by the agency's Pilot Drug Evaluation Staff because the drug is an inhaled corticosteroid. Rhone-Poulenc Rorer has agreed to conduct Phase IV postmarketing studies on Nasacort. In a June 21 letter to FDA's Pilot Drug Evaluation Staff, the company committed to: "a research program with a goal of achieving unique particle size distribution profiles for Azmacort and Nasacort"; "a new design and analysis methodology for dose-response and therapeutic equivalence studies"; "a dose-response study with the marketed Nasacort formulation"; and "a therapeutic equivalence trial comparing the new formulation to the marketed formulation." The company said it plans a "major U.S. launch of the product." Nasacort will be introduced to physicians on Aug. 19 and detailed by RPR's 900-person sales force. Pricing, advertising and promotional plans have yet to be announced. FDA's approval letter for Nasacort notes that the company and the agency will work together on creating an appropriate introductory campaign for the drug. "As a reflection of our mutual understanding of the importance of initial promotional campaigns on physicians' use of a new drug," the approval letter states, "we note your commitment to work with us and with the Division of Drug Advertising and Labeling on this advertising program to develop an introductory campaign satisfactory to all concerned." Rorer submitted the NDA for Nasacort on Jan. 22, 1988 and resubmitted an application on Dec. 22, 1988. Rorer filed the Nasacort NDA electronically in conjunction with Research Data Corp.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts